190 related articles for article (PubMed ID: 33598527)
21. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
[TBL] [Abstract][Full Text] [Related]
22. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid.
Gobom J; Parnetti L; Rosa-Neto P; Vyhnalek M; Gauthier S; Cataldi S; Lerch O; Laczo J; Cechova K; Clarin M; Benet AL; Pascoal TA; Rahmouni N; Vandijck M; Huyck E; Le Bastard N; Stevenson J; Chamoun M; Alcolea D; Lleó A; Andreasson U; Verbeek MM; Bellomo G; Rinaldi R; Ashton NJ; Zetterberg H; Sheardova K; Hort J; Blennow K
Clin Chem Lab Med; 2022 Jan; 60(2):207-219. PubMed ID: 34773730
[TBL] [Abstract][Full Text] [Related]
23. Influence of kidney function and CSF/serum albumin ratio on plasma Aβ42 and Aβ40 levels measured on a fully automated platform in patients with Alzheimer's disease.
Verde F; Milone I; Dubini A; Colombrita C; Perego A; Solca F; Maranzano A; Ciusani E; Poletti B; Ratti A; Torresani E; Silani V; Ticozzi N
Neurol Sci; 2023 Sep; 44(9):3287-3290. PubMed ID: 37284933
[TBL] [Abstract][Full Text] [Related]
24. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.
Mo Y; Stromswold J; Wilson K; Holder D; Sur C; Laterza O; Savage MJ; Struyk A; Scheltens P; Teunissen CE; Burke J; Macaulay SL; Bråthen G; Sando SB; White LR; Weiss C; Cowes A; Bush MM; DeSilva G; Darby DG; Rainey-Smith SR; Surls J; Sagini E; Tanen M; Altman A; Luthman J; Egan MF
Alzheimers Dement (Amst); 2017; 6():201-209. PubMed ID: 28349119
[TBL] [Abstract][Full Text] [Related]
25. The dynamics of plasma biomarkers across the Alzheimer's continuum.
Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
[TBL] [Abstract][Full Text] [Related]
26. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
[TBL] [Abstract][Full Text] [Related]
27. Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults.
Guo T; Landau SM; Jagust WJ;
Alzheimers Res Ther; 2021 Oct; 13(1):174. PubMed ID: 34654465
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
[TBL] [Abstract][Full Text] [Related]
29. Relationship Between Cerebrospinal Fluid Alzheimer's Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review.
Kurihara M; Kondo S; Ohse K; Nojima H; Kikkawa-Saito E; Iwata A
J Alzheimers Dis; 2024; 99(3):1077-1092. PubMed ID: 38759016
[TBL] [Abstract][Full Text] [Related]
30. Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40.
Wisch JK; Gordon BA; Boerwinkle AH; Luckett PH; Bollinger JG; Ovod V; Li Y; Henson RL; West T; Meyer MR; Kirmess KM; Benzinger TLS; Fagan AM; Morris JC; Bateman RJ; Ances BM; Schindler SE
Alzheimers Dement (Amst); 2023; 15(1):e12405. PubMed ID: 36874595
[TBL] [Abstract][Full Text] [Related]
31. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
Wilson EN; Young CB; Ramos Benitez J; Swarovski MS; Feinstein I; Vandijck M; Le Guen Y; Kasireddy NM; Shahid M; Corso NK; Wang Q; Kennedy G; Trelle AN; Lind B; Channappa D; Belnap M; Ramirez V; Skylar-Scott I; Younes K; Yutsis MV; Le Bastard N; Quinn JF; van Dyck CH; Nairn A; Fredericks CA; Tian L; Kerchner GA; Montine TJ; Sha SJ; Davidzon G; Henderson VW; Longo FM; Greicius MD; Wagner AD; Wyss-Coray T; Poston KL; Mormino EC; Andreasson KI
Alzheimers Res Ther; 2022 Nov; 14(1):172. PubMed ID: 36371232
[TBL] [Abstract][Full Text] [Related]
32. Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration.
Ortner M; Goldhardt O; Diehl-Schmid J; Yakushev I; Lanz K; Hedderich DM; Manuilova E; Simon M; Weinberger JP; Grimmer T
J Prev Alzheimers Dis; 2022; 9(3):491-498. PubMed ID: 35841250
[TBL] [Abstract][Full Text] [Related]
33. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging.
Doecke JD; Ward L; Burnham SC; Villemagne VL; Li QX; Collins S; Fowler CJ; Manuilova E; Widmann M; Rainey-Smith SR; Martins RN; Masters CL;
Alzheimers Res Ther; 2020 Mar; 12(1):36. PubMed ID: 32234072
[TBL] [Abstract][Full Text] [Related]
34. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.
Salvadó G; Molinuevo JL; Brugulat-Serrat A; Falcon C; Grau-Rivera O; Suárez-Calvet M; Pavia J; Niñerola-Baizán A; Perissinotti A; Lomeña F; Minguillon C; Fauria K; Zetterberg H; Blennow K; Gispert JD;
Alzheimers Res Ther; 2019 Mar; 11(1):27. PubMed ID: 30902090
[TBL] [Abstract][Full Text] [Related]
35. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
Zwan M; van Harten A; Ossenkoppele R; Bouwman F; Teunissen C; Adriaanse S; Lammertsma A; Scheltens P; van Berckel B; van der Flier W
J Alzheimers Dis; 2014; 41(3):801-7. PubMed ID: 24705549
[TBL] [Abstract][Full Text] [Related]
36. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
[TBL] [Abstract][Full Text] [Related]
37. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease.
Barthélemy NR; Saef B; Li Y; Gordon BA; He Y; Horie K; Stomrud E; Salvadó G; Janelidze S; Sato C; Ovod V; Henson RL; Fagan AM; Benzinger TLS; Xiong C; Morris JC; Hansson O; Bateman RJ; Schindler SE
Nat Aging; 2023 Apr; 3(4):391-401. PubMed ID: 37117788
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.
Pan C; Korff A; Galasko D; Ginghina C; Peskind E; Li G; Quinn J; Montine TJ; Cain K; Shi M; Zhang J
J Alzheimers Dis; 2015; 45(3):709-19. PubMed ID: 25613100
[TBL] [Abstract][Full Text] [Related]
39. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
[TBL] [Abstract][Full Text] [Related]
40. CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab.
Nisenbaum L; Martone R; Chen T; Rajagovindan R; Dent G; Beaver J; Rubel C; Racine A; He P; Harrison K; Dean R; Vandijck M; Haeberlein SB
Alzheimers Dement; 2023 Aug; 19(8):3379-3388. PubMed ID: 36795603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
